Samaee, H. and Mohsenzadegan, M. and Ala, S. and Maroufi, S.S. and Moradimajd, P. (2020) Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. International Immunopharmacology, 89.
|
Text
Tocilizumab for treatment patients with COVID-19 Recommended medication for novel disease.pdf Download (572kB) | Preview |
Abstract
The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Recently Tocilizumab has been introduced to treat patients with COVID-19 and researchers are investigating further the efficacy of this drug for different are patients. In Iran and China, some reports showed a positive effect of Tocilizumab on Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some patients, CT scan showed reduced infiltration, however in other no change was observed. Unfortunately, until now there has been no definitive and effective treatment for patients with COVID-19. Although Tocilizumab has been accepted by China Health Commission to treat infected patients, its positive effects still cannot be predicted in all patients. Based on evidence of the Tocilizumab's effect on the SARS COV 2, researchers hope this drug will make effective and promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 virus. The present study provides an overview of respiratory inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2. © 2020 Elsevier B.V.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 5 |
| Uncontrolled Keywords: | interleukin 6; tocilizumab; interleukin 6; interleukin 6 receptor; monoclonal antibody; tocilizumab, arthritis; coronavirus disease 2019; cytokine release syndrome; digestive system perforation; diverticulitis; drug hypersensitivity; drug mechanism; headache; herpes zoster; human; hypertension; injection site erythema; injection site pruritus; injection site rash; injection site swelling; juvenile rheumatoid arthritis; lung fibrosis; malignant neoplasm; mycosis; nonhuman; priority journal; respiratory tract infection; respiratory tract inflammation; Review; sepsis; Severe acute respiratory syndrome coronavirus 2; tuberculosis; complication; drug therapy; physiology, Antibodies, Monoclonal, Humanized; COVID-19; Humans; Interleukin-6; Receptors, Interleukin-6; SARS-CoV-2 |
| Subjects: | WC Communicable Diseases QV Pharmacology |
| Depositing User: | eprints admin |
| Date Deposited: | 08 May 2021 09:21 |
| Last Modified: | 08 May 2021 09:21 |
| URI: | http://eprints.iums.ac.ir/id/eprint/33538 |
Actions (login required)
 |
View Item |
